Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of COVI-VAC (CoviLiv) in Healthy Young Adults
NCT04619628Phase 1Completed
- Sponsor
- Codagenix
- Start
- Dec 2020
- Primary completion
- Jun 2021
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of COVI-VAC in coronavirus disease 2019 (COVID-19) (7 arms), sponsored by Codagenix. Primary endpoints: Reactogenicity, Adverse Events and 1 more. Started Dec 2020; status: completed.
02
Drugs
COVI-VAC
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04619628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04619628.